Breaking News, Collaborations & Alliances

ImmunoGen Earns Bayer Milestone

Bayer HealthCare Pharmaceuticals has submitted an IND application for the TAP compound, BAY 94-9343, triggering a $2 million milestone payment to ImmunoGen.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bayer HealthCare Pharmaceuticals has submitted an IND application for the TAP compound, BAY 94-9343, triggering a $2 million milestone payment to ImmunoGen. In preclinical testing, BAY 94-9343 demonstrated potent, targeted anticancer activity against mesothelin-expressing tumors. Bayer is developing BAY 94-9343 under an agreement with ImmunoGen that grants Bayer exclusive rights to use the company’s maytansinoid TAP technology to develop anticancer therapeutics that target mesothelin. ImmunoGen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters